An engineered hybrid cell vesicle, and a preparation method and application thereof in preparing a melanoma vaccine

CN122326533APending Publication Date: 2026-07-03SHANGHAI DERMATOLOGY HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI DERMATOLOGY HOSPITAL
Filing Date
2026-04-09
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Existing whole-cell tumor vaccines suffer from low immunogenicity, limited antigen presentation efficiency, poor lymph node targeting, and short retention time in activating anti-tumor immune responses, thus affecting immune activation efficiency.

Method used

Pyroptosis-treated melanoma cells were hybridized with immune cells, and hybrid cell vesicles were formed through multi-stage compression. DSPE-PEG modified with the autophagy-inducible peptide Beclin-1 was loaded onto the surface of the vesicles to promote antigen processing and presentation.

Benefits of technology

It improved the immunogenicity of the vaccine, enhanced its lymph node enrichment capacity, promoted antigen processing and presentation, and demonstrated good immune response. It also showed high safety and a stable and reproducible preparation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122326533A_ABST
    Figure CN122326533A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to an engineered hybrid cell vesicle, its preparation method, and its application in the preparation of melanoma vaccines. This invention hybridizes pyroptosis-treated melanoma cells with immune cells to obtain hybrid cell vesicles, which helps improve the immunogenicity of the vaccine system, enhances the enrichment capacity to immune organs such as lymph nodes, and promotes antigen processing and presentation. It exhibits good immune response in tumor immune-related models with high safety. This invention loads an autophagy-inducing peptide modified with distearate phosphatidylethanolamine-polyethylene glycol onto the surface of the hybrid cell vesicles, directly acting on the core autophagy initiation pathway to induce controllable and functional autophagy enhancement. Structurally, it is more suitable for engineered loading onto the hybrid cell vesicle membrane, thereby achieving precise regulation of the antigen presentation function of immune cells. The preparation process of this invention is stable and reproducible, and has potential for further applications.
Need to check novelty before this filing date? Find Prior Art